McGill University - Currie Gymnasium
Montreal, Quebec, H2W 1S4, Canada
Location status: Recruiting
Location contact
Caroline Paquette, PhD
PRINCIPAL_INVESTIGATOR
Tomoha Ogawa, BA
CONTACT
NCT Number: NCT07351032
The purpose of this study is to understand how a specific brain area, the Posterior Parietal Cortex (PPC), plays a role in movement transfer from walking on a split-belt treadmill (SBT) to walking on the ground in people with Parkinson's disease (PwPD).
Here, investigators will apply repeated transcranial magnetic stimulation (rTMS) to upregulate the PPC. Then, the differences in the gait parameters between pre- and post-interventions will be compared between the TMS-active and the TMS-sham.
Interested in participating?
Request Info50 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H2W 1S4, Canada
Location status: Recruiting
Caroline Paquette, PhD
PRINCIPAL_INVESTIGATOR
Tomoha Ogawa, BA
CONTACT
The split-belt training has been shown to modulate gait in PwPD, but the skill transfer from the SBT training to the overground walking is poorly understood.
In this project, the subjects will visit the lab on three occasions: day 1 is for the clinical assessment based on the questionnaires, the 10-Meter Walk Task, as well as finding TMS targets and thresholds for the tibialis anterior (TA) and first dorsal interosseous (FDI) muscles, day 2 and day 3 are for either rTMS-active or rTMS-sham intervention. The second and third visits will take place at least 48h a part to ensure that the rTMS effects are washed out between visits.
During these two visits, the participants will first perform pre-overground walking tests (3 minutes): straight walking, steering, and turning, followed by pre-SBT adaptation tests (4 minutes) where they will adapt their gait to the asymmetrical belt that changes every 30 seconds. After these walking tests, the threshold measured on the first day will be validated, and the cortical excitability of the PPC will be measured by using a dual-coil: one is over the TA hotspot, and the other is over the PPC. Then, rTMS or sham intervention will be performed, followed by measuring the cortical excitability of the PPC. Immediately after that intervention, the participants will train on the SBT for 30 minutes in total (with a one-minute break every 5 minutes) with the speed of the belt changing every 30 seconds. Following the SBT training, the participants will perform post-overground and post-SBT adaptation tests. Lastly, the cortical excitability of the PPC will be measured.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ACTIVE: intermittent Theta Burst Stimulation (a patterned form of rTMS). The participants will receive iTBS (50hz bursts at 5Hz for 600 pulses for a total duration of 3-minutes) over the right PPC at 80% RMT of the FDI.
SHAM: 2 coils on top of each other will be used instead of 1. The coil furthest to the head will be reversed. The coil on the head will not be stimulating but the reversed coil will (current directed away from the brain) with stimulate with the same parameters at the active stimulation (intermittent Theta Burst Stimulation (a patterned form of rTMS). The participants will receive iTBS (50hz bursts at 5Hz for 600 pulses for a total duration of 3-minutes) over the right PPC at 80% RMT of the FDI.
Time frame: Day 2 and Day 3
The forward distance travelled by a foot during a gait cycle (cm) measured during overground walking and on the SBT with the Ambulatory Parkinson's Disease Monitoring (APDM) mobility lab system.
A higher score indicates better gait control.
Time frame: Day 2 and Day 3
The percentage of the gait cycle when both feet are in contact with the ground (%) will be measured during overground walking and on the SBT with the Ambulatory Parkinson's Disease Monitoring (APDM) mobility lab system.
A higher score indicates a longer time for both feet to be in contact with the ground.
Time frame: Day 2 and Day 3
The number of steps per minute will be measured during overground walking and on the SBT with the Ambulatory Parkinson's Disease Monitoring (APDM) mobility lab system.
A higher score indicates better gait control.
Time frame: Day 2 and Day 3
The speed of the subject, measured as the distance traveled in the gait cycle divided by the gait cycle duration (m/s) during overground walking and on the SBT will be measured with the Ambulatory Parkinson's Disease Monitoring (APDM) mobility lab system.
A higher score indicates better gait control.
Time frame: Day 2 and Day 3
The peak angular velocity of the turn (deg/s) during overground walking will be measured with the Ambulatory Parkinson's Disease Monitoring (APDM) mobility lab system.
The higher score indicates better turning performance.
Time frame: Day 2 and Day 3
The number of steps taken in one turn during overground walking will be measured with the Ambulatory Parkinson's Disease Monitoring (APDM) mobility lab system.
The higher score indicates better turning performance.
Time frame: Day 2 and Day 3
The distance between the heels of two consecutive steps (m) during overground walking will be measured with a custom MATLAB script.
The higher score indicates better gait control.
Time frame: Day 2 and Day 3
The cortical excitability will be assessed using a dual coil setup where two coils are placed on 2 different locations of the scalp at the same time. One coil will be positioned over the PPC, and the other over the TA hotspot.
A total of 50 stimuli will be randomly delivered: 25 pulses will be applied solely over the TA hotspot (TA), and the other 25 paired pulses in which a PPC stimulus precedes the TA stimulus by 4 milliseconds (PPC + TA).
Cortical excitability will be quantified by using the following ratio: (PPC + TA) / (TA).
The higher score indicates the greater excitability of the neurons along the PPC-M1 pathway.
Contact information is provided by the study sponsor or research team.
McGill University
Other
Neural Mechanism of Skill Transfer in Parkinson's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07590700
Basal Ganglia Diseases, Behavior
Hatay, Antakya, Turkey (Türkiye)
View Trial DetailsNCT07190404
Basal Ganglia Diseases, Brain Diseases
St Louis, Missouri, United States
View Trial DetailsNCT07193303
Basal Ganglia Diseases, Brain Diseases
Kahramanmaraş, Onikişubat, Turkey (Türkiye)
View Trial DetailsNCT07151378
Basal Ganglia Diseases, Brain Diseases
Saarlouis, Saarland, Germany
View Trial Details